Experimental CAR-T therapy takes on tough leukemia

NCT ID NCT07617285

Recruiting now Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial is testing a new type of CAR-T cell therapy, called CT0890B, for people with acute myeloid leukemia (AML) that has come back or not responded to treatment. The therapy uses donor-derived immune cells that are engineered to target a protein called NKG2DL on leukemia cells. Up to 27 participants will receive the cells along with chemotherapy, and researchers will monitor safety and any signs that the leukemia is reduced.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: allogeneic CAR-T cells (CT0890B) plus chemotherapy conditioning
What this could lead to: If successful, this could provide a new treatment option for patients with hard-to-treat acute myeloid leukemia who have run out of standard therapies.
What could go wrong: This is a very early phase 1 trial with only 27 participants, so safety and effectiveness are not yet proven. CAR-T therapy can cause severe side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for AML are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AML REFRACTORY/RELAPSE ACUTE MYELOID LEUKEMIA

Contacts and locations

Locations

Peking University People's Hospital
RECRUITING

Beijing, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.